Drug intelligence / Profile preview

TSR-026

Development stage: Preclinical
Lead developer: Therapeutic Systems Research Laboratories
Modality: Small Molecules
Administration: Oral

Overview

TSR-026 is an orally bioavailable small-molecule prodrug and analogue of the neuraminidase inhibitor zanamivir, developed by TSRL to enable convenient oral treatment of influenza. By using a proprietary transporter-targeted absorption technology, TSR-026 is designed to enhance intestinal uptake and systemic exposure of a zanamivir-like antiviral that is otherwise limited to inhaled administration, potentially improving treatment of respiratory flu in patients with compromised lung function while maintaining a favorable resistance profile against circulating influenza virus strains.[2][7][11]

Targets

HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)

Beyond the preview

Go deeper on TSR-026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSR-026.

Explore the full profile